- Home
- IDE vs LYEL Comparison
IDE vs LYEL Comparison
Compare IDE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDE
- LYEL
- Stock Information
- Founded
- IDE 2010
- LYEL 2018
- Country
- IDE United States
- LYEL United States
- Employees
- IDE N/A
- LYEL N/A
- Industry
- IDE Finance/Investors Services
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- IDE Finance
- LYEL Health Care
- Exchange
- IDE Nasdaq
- LYEL Nasdaq
- Market Cap
- IDE 187.9M
- LYEL 207.7M
- IPO Year
- IDE N/A
- LYEL 2021
- Fundamental
- Price
- IDE $12.45
- LYEL $12.64
- Analyst Decision
- IDE
- LYEL Sell
- Analyst Count
- IDE 0
- LYEL 2
- Target Price
- IDE N/A
- LYEL $15.00
- AVG Volume (30 Days)
- IDE 33.5K
- LYEL 33.8K
- Earning Date
- IDE 01-01-0001
- LYEL 11-06-2025
- Dividend Yield
- IDE 8.83%
- LYEL N/A
- EPS Growth
- IDE N/A
- LYEL N/A
- EPS
- IDE N/A
- LYEL N/A
- Revenue
- IDE N/A
- LYEL $60,000.00
- Revenue This Year
- IDE N/A
- LYEL N/A
- Revenue Next Year
- IDE N/A
- LYEL N/A
- P/E Ratio
- IDE N/A
- LYEL N/A
- Revenue Growth
- IDE N/A
- LYEL 11.11
- 52 Week Low
- IDE $8.61
- LYEL $7.65
- 52 Week High
- IDE $10.46
- LYEL $32.00
- Technical
- Relative Strength Index (RSI)
- IDE 60.15
- LYEL 57.81
- Support Level
- IDE $12.37
- LYEL $11.93
- Resistance Level
- IDE $12.39
- LYEL $13.62
- Average True Range (ATR)
- IDE 0.11
- LYEL 0.70
- MACD
- IDE -0.01
- LYEL 0.02
- Stochastic Oscillator
- IDE 68.97
- LYEL 65.81
About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest
Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.